• 1
    Ravid R, Swaab DF, Van Zwieten EJ & Salehi A (1995) Controls are what makes a brain bank go round. In Neuropathological Diagnostic Criteria for Brain Banking, Biomedical and Health Research, Vol. 10 (Cruz-Sánchez FF, Cuzner ML & Ravid R eds), pp. 413. IOS Press, Amsterdam, The Netherlands.
  • 2
    Hulette CM (2003) Brain banking in the United States. J Neuropathol Exp Neurol 62, 715722.
  • 3
    Kretzschmar H (2009) Brain banking: opportunities, challenges and meaning for the future. Nat Rev Neurosci 10, 7078.
  • 4
    Cruz-Sánchez FF, Ravid R & Cuzner ML (1995) The European Brain Bank Network (EBBN) and the need of standardized neuropathological criteria for brain tissue cataloguing. In Neuropathological Diagnostic Criteria for Brain Banking, European Union Biomedical and Health Research, Vol. 10 (Cruz-Sánchez FF, Cuzner ML & Ravid R eds), pp. 13. IOS Press, Amsterdam, The Netherlands.
  • 5
    Cruz-Sánchez FF, Mordini E & Ravid R (1997) Ethical aspects to be considered in brain banking. Ann Ist Super Sanità 33, 477482.
  • 6
    Ravid R (2008) Standard Operating Procedures, ethical and legal regulations in BTB (Brain/Tissue/Bio) banking: what is still missing? Cell Tissue Bank 9, 151167.
  • 7
    Jellinger K & Mizuno Y (2003) Parkinson’s disease. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders (Dickson D ed.), pp. 159187. ISN Neuropathol. Press, Bassel.
  • 8
    Hughes AJ, Daniel SE, Ben-Shlomo Y & Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861870.
  • 9
    Gallagher DA, Lees AJ & Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25, 24932500.
  • 10
    Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R et al. (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134, 14931505.
  • 11
    Ravid R (2009) Biobanks for biomarkers in neurological disorders: The Da Vinci bridge for optimal clinico-pathological connection. J Neurol Sci 283, 119126.
  • 12
    Vonsattel JPG, del Amaya MP & Keller CH (2008) Twenty-first century brain banking. Processing brains for rseerarch: the Columbia University methods. Acta Neuropathol 115, 509532.
  • 13
    Ravid R, Van Zwieten EJ & Swaab DF (1992) Brain Banking and the human hypothalamus – factors to match for, pitfalls and potentials. In Progress in Brain Res, Vol. 93 (Swaab DF, Hofman MA, Mirmiran M, Ravid R & Van Leeuwen FW eds), pp. 8395. Elsevier Science Publishers, Amsterdam, The Netherlands.
  • 14
    Ferrer I, Martinez A, Boluda S, Parchi P & Barrachina M (2008) Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 9, 181194.
  • 15
    Braak H, del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH & Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24, 197211.
  • 16
    Parkkinen L, Kauppinen T, Pirttilä T, Autere JM & Alafuzoff I (2005) α-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57, 8291.
  • 17
    Dickson DW (2001) Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol 14, 423432.
  • 18
    Dickson DW, Fujishiro H, DelleDonne A, Josephs K, Frigerio R, Burnett M, Parisi JE, Klos KJ & Ahlskog JE (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15(Suppl 3), S15.
  • 19
    Ferrer I, Martinez A, Blanco R, Dalfó E & Carmona M (2011) Neuropathology of sporadic Parkinson disease (PD) before the appearance of parkinsonism: incidental PD. J Neural Transm 118, 821839.
  • 20
    Ferrer I (2009) Early involvement of the cerebral cortex in Parkinson’s disease: convergence of multiple metabolic defects. Progr Neurobiol 88, 89103.
  • 21
    Navarro A, Boveris A, Bández MJ, Sánchez-Pino MJ, Gómez C, Muntané G & Ferrer I (2009) Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med 46, 15741580.
  • 22
    Martínez A, Portero-Otin M, Pamplona R & Ferrer I (2010) Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 20, 281297.
  • 23
    Dalfó E, Portero-Otín M, Ayala V, Martínez A, Pamplona R & Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64, 816830.
  • 24
    Dalfó E & Ferrer I (2008) Early α-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol Aging 29, 408417.
  • 25
    Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS & Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s disease. J Biol Chem 279, 1325613264.
  • 26
    Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS & Li L (2005) Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280, 1164811655.
  • 27
    Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, Bostwick DE, Gearing M, Levey AI, Chin LS & Li L (2006) Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281, 1081610824.
  • 28
    Gómez A & Ferrer I (2009) Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res 87, 10021013.
  • 29
    Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG et al. (2008) Neuronal gene expression correlates of Parkinson’s disease with dementia. Mov Disord 23, 15881595.
  • 30
    Grünblatt E, Zander N, Bartl J, Jie L, Monoranu CM, Arzberger T, Ravid R, Roggendorf W, Gerlach M & Riederer P (2007) Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease. J Alzheimers Dis 12, 291311.
  • 31
    Miñones-Moyano E, Porta S, Escaramís G, Rabionet R, Iraola S, Espinosa Y, Ferrer I, Estivill X & Martí E (2011) Early downregulation of miR-34b and miR-34c in brain may contribute to mitochondrial dysfunction in Parkinson’s disease. Hum Mol Genet 20, 30673078.
  • 32
    Crecelius A, Götz A, Arzberger T, Fröhlich T, Arnold GJ, Ferrer I & Kretzschmar HA (2008) Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 8, 12761291.
  • 33
    Shi M, Caudle WM & Zhang J (2009) Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis 35, 157164.
  • 34
    Caudle WM, Bammler TK, Lin Y, Pan S & Zhang J (2010) Expert Rev Neurother. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother 10, 925942.
  • 35
    Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C & Zhang J (2008) Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol 67, 117124.
  • 36
    Yang H, Zhou X, Liu X, Yang L, Chen Q, Zhao D, Zuo J & Liu W (2011) Mitochondrial dysfunction induced by knockdown of mortalin is rescued by Parkin. Biochem Biophys Res Commun 410, 114120.
  • 37
    Fabelo N, Martín V, Santpere G, Marín R, Torrens L, Ferrer I & Díaz M (2011) Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease. Mol Med 17, 11071118.
  • 38
    Yong SW, Yoon JK, An YS & Lee PH (2007) A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol 14, 13571362.
  • 39
    Wallin A, Ekberg S, Lind K, Milos V, Granérus AK & Granérus G (2007) Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson’s disease – a rCBF scintigraphic study. Acta Neurol Scand 116, 347354.
  • 40
    Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V & Eidelberg D (2007) Changes in network activity with the progression of Parkinson’s disease. Brain 130, 18341846.
  • 41
    Huang C, Mattis P, Perrine K, Brown N, Dhawan V & Eidelberg D (2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70, 14701477.
  • 42
    Bohnen NI, Koeppe RA, Minoishima S, Giordani B, Albin RL, Frey KA & Kuhl DE (2011) Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 52, 848855.
  • 43
    Muntané G, Dalfó E, Martinez A & Ferrer I (2008) Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies. Neuroscience 152, 913923.
  • 44
    Schulz-Schaeffer WJ (2010) The synaptic pathology of α-synuclein in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120, 131143.
  • 45
    Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H & Wakabayashi K (2010) Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T synuclein transgenic mice. Acta Neuropathol 120, 145154.
  • 46
    Dalfó E, Barrachina M, Rosa JL, Ambrosio S & Ferrer I (2004) Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol Dis 16, 9297.
  • 47
    Alberio T, Lopiano L & Fasano M (2012) Cellular models to investigate pathways in Parkinson’s disease. FEBS J 279, doi:10.1111/j.1742-4658.2012.08516.x.
  • 48
    Blandini F & Armentero MT (2012) Animal models of Parkinson’s disease. FEBS J 279, doi:10.1111/j.1742-4658.2012.08491.x.